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Persistent immune activation characterises HIV infection and is associated with depletion of CD4+ T-cells and increased risk of
disease progression. Early loss of gut mucosal integrity results in the translocation of microbial products such as lipopolysaccharide
(LPS) into the systemic circulation. This is an important source of on-going immune stimulation. The purpose of this study was to
determine levels of CD4+ T-cell activation (%CD25 expression) and apoptosis (% annexin V/7-AAD) in asymptomatic, untreated
HIV infection at baseline and after stimulation with LPS and incubation with or without vitamin C and N-acetylcysteine. LPS
induced a significant (𝑃 < 0.03) increase in %CD25 expression, annexin V, and 7-AAD in HIV positive individuals. NAC in
combination with vitamin C, significantly (𝑃 = 0.0018) reduced activation and early apoptosis of CD4+ T-cells to a greater
degree than with either antioxidant alone. Certain combinations of antioxidants could be important in reducing the harmful effects
of chronic immune activation and thereby limit CD4+ T-cell depletion. Importantly, we showed that CD4+ T-cells of the HIV
positive group responded better to a combination of the antioxidants at this stage than those of the controls.Therefore, appropriate
intervention at this asymptomatic stage could rescue the cells before repetitive activation results in the death of CD4+ T-cells.
1. Introduction
HIV infection is characterized by chronic immune activation
and inflammatory cytokine production [1, 2]. The consistent
activation of CD4 and CD8 T-cells is associated with deple-
tion of CD4 T-cells and increased risk of disease progression
to AIDS [3]. Furthermore, markers of immune activation
have been shown to be stronger predictors of progression
to AIDS than either the CD4 counts or viral loads [4–6].
In particular, increased T-cell activation has been associated
with AIDS suggesting that activated T-cells are susceptible to
apoptosis [7]. In addition, elevated levels of CD38, a marker
of immune activation on CD4 and CD8 T-cell, predict a
rapid decrease of CD4 T-cells and a shorter survival rate,
independent of HIV viral loads [8, 9].
The significant depletion of memory-type CD4 T-cells
lining the gastrointestinal tract (GIT) mucosa in early
HIV infection results in the breakdown of the mucosa
and on-going translocation of microbial products such as
lipopolysaccharide (LPS) across the epithelial surface [1,
10]. LPS induces activation of innate immune cells such as
monocytes and dendritic cells resulting in increased oxidative
stress; depletion of antioxidant defence mechanisms and
an increased susceptibility to apoptosis [1, 11]. In addition,
CD4 T-lymphocytes have been shown to express-toll-like
receptor-4 (TLR4), which is a receptor for LPS [12, 13].
Triggering of TLR4 activates various signalling pathways
such asmitogen-activated protein kinases (MAPKs), p38, and
JNK, which induce activation of transcription factor nuclear
factor of kappa B (NF-𝜅B) and subsequent production of
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proinflammatory cytokines, chemokines, antimicrobial pep-
tides, and other defence molecules such as ROS [13]. The
proinflammatory cytokines such as TNF-𝛼, are capable of
activating innate immune cells to produce more ROS. ROS
and proinflammatory cytokines in turn induce activation of
both the extrinsic and intrinsic pathways of apoptosis. The
role of in vitro stimulation with lipopolysaccharide (LPS) on
T-cell activation in HIV has been explored only minimally
[14, 15]. The first study to date in HIV used CD38 and
HLA-DR as the activation markers which were conducted on
HIV positive patients who were on antiretroviral treatment
[15]. Few studies have investigated the inhibitory effects
by antioxidants on immune activation and apoptosis in
asymptomatic, untreated HIV infection. In the current study,
we investigated the effects of vitamin C and NAC on LPS-
induced upregulation of interleukin receptor-2 receptor alpha
chain, (CD25), as a marker of LPS-induced activation of
CD4+T-cells after overnight incubation in untreated HIV
infection.
In this study, therefore, levels of immune activation and
apoptosis were measured before and after stimulation with
LPS and incubation with selected antioxidants (vitamin C
andNAC) in untreated HIV positive individuals.These levels
were compared to a control group. We developed an assay
that demonstrates the response of CD4+ T-cells to LPS-
induced stimulation and, further, showed the inhibitory effect
of antioxidants in this process.
2. Materials and Methods
2.1. Study Population and Design. In this cross-sectional
study, twenty untreated, asymptomatic HIV positive individ-
uals and 20 controls (32 females and 8 males) were sourced
from a single HIV testing and prevention primary health
clinic in Crossroads, Cape Town, South Africa. The median
age of the participants was 32 years (range 22–42). There was
no significant difference in age between the two groups. The
HIV positive group had a significantly (𝑃 = 0.0003) lower
CD4 count compared to the control group. The patients’
demographics are summarised in Table 1. Informed consent
was taken from all the participating subjects. Inclusion
criteria for the study participants were 21 years or older,
individuals with HIV infection and CD4 counts >200; not
on antiretrovirals (ARVs) or any other chronic medication or
antioxidant supplements. Exclusion criteria included patients
with tuberculosis (TB) or other coinfections and those
receiving antiretroviral therapy, anti-TB treatment or other
antibiotic treatment, antioxidant supplementation, mineral
and vitamins supplements, aspirin, or any other drug, for
example, anti-inflammatory.
Ethics approval was obtained from both the clinical site,
University of Cape Town: REC: REF: 417/2006 and laboratory
site, University of Stellenbosch HREC N07/09/197.
2.2. Reagents. Flow-check Fluorospheres, Flow-set Fluoro-
spheres, CD4-PE, CD4-APC, CD25-PE, and annexin V-
FITC/7AAD-PE kit were obtained from Beckman Coulter,
Miami Florida Inc. (USA). FC 500 cytometer with two
lasers, from Beckman Coulter, Miami, Florida, USA, FL,
was used to acquire the data. L-ascorbic acid stock powder
or vitamin C (C
6
H
8
O
6;
molecular weight 176.12 g/mol; 25 g
powder) and N-acetyl-L-cysteine stock powder (C
5
H
9
NO
3
S;
25 g powder) were purchased from Sigma-Aldrich (South
Africa).
2.3. Sample Preparation. Blood was drawn into two 10mL
tubes withHeparin, one 5mL tubewith EDTA (for viral load)
and one 5mL tube with citrate (for D-dimers). Samples were
then couriered from the clinic to the laboratory within two
hours of collection.
Heparinized whole blood samples were incubated with
antioxidants for 20min then stimulated with LPS, incubated
overnight, and analysed on flow cytometer. Briefly, 100 𝜇L
of blood was added into the labelled tubes and 30 𝜇L of
vitamin C (10mM) or 20𝜇L of NAC (5 𝜇M) vortexed gently
and incubated for 20 minutes. An additional tube was
prepared with the “cocktail” of both antioxidants. After 20-
minute incubation of the samples at 37∘C with 5% carbon
dioxide (CO
2
), 20𝜇L of LPS (2𝜇g/mL) was added. The
dosages (2𝜇g/mL LPS, 10mM vitamin C, and 5𝜇M NAC)
used in this study were chosen for these experiments after
a rigorous optimization study on the effects of tempera-
ture, time, and concentration on LPS-induced whole blood
activation and antioxidant intervention in asymptomatic
untreated HIV infection previously done in our lab (data
not shown); these doses were chosen (data not shown).
The samples were incubated overnight and analysed on flow
cytometer.
For each sample, 100𝜇L of blood was added to appropri-
ately labelled Beckman’s flow tubes and 10𝜇L of monoclonal
antibody mix was added. The sample was vortexed gently
and incubated at room temperature for 15 minutes in the
dark after which 500 𝜇L of fluorescein-activated cell sorting
(FACS) lysing solution was added. The sample was vortexed
gently and incubated for 15 minutes at room temperature.
After incubation, 250𝜇L of ice cold staining buffer and 250𝜇L
of binding buffer were added. The sample was spun at 300 g
for 5minutes after which 750𝜇L of supernatant was removed.
The pellets were resuspended, 200𝜇L of staining buffer and
and 200𝜇L of binding buffers were added and analysed on
flow cytometer.
2.4. Flow Cytometry Analysis. An FC 500 flow cytome-
ter (Beckman Coulter, Miami, FL, USA) with two lasers,
five fluorescence channels, and CXP analysis software were
used in this study. Alignment of the lasers was performed
with a mixture of Flow-check and Flow-check beads. The
appropriate voltages were determined and standardized with
a mixture of Flow-set and Flow-set beads. Full matrix
colour compensation was done using FITC, PE, APC, and
PerCP/PC5 stained whole blood cells prepared using the
lyse and wash method. A panel was created for test analysis
using the cytometer settings established with flow-set and
full matrix colour compensation. CXP and FCS Express V3
software programs were used to analyse the flow cytometry
data.
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Table 1: Demographics characteristics of both the HIV positive and control groups.
Parameter HIV positive group (𝑛 = 20) Controls (𝑛 = 20) 𝑃 values
Male : female 5 : 15 3 : 17
Median age (yrs) 31.8 (27–35) 30.3 (22–35) 0.43
Range 21–51 21–48
Median CD4 cells/mm3 411 (265–634) 753 (564–870) 0.0012∗∗
Median viral load (copies/mL) 45705 (2174–157294) ND
Log viral load 4.0 (3.1–5.4)
All the values in columns are median (interquartile range) of HIV positive (𝑛 = 20) individuals and controls (𝑛 = 20). ∗∗Significant at 𝑃 = 0.05.
2.5. Data Acquisition and Analysis for Apoptosis. For apop-
tosis, plot quadrants were set using unstained cells for every
sample such that the negative annexin V cells and 7-AAD
negative population lay in the first decade of the𝑌 and𝑋 axis.
A sequential gating strategy, by first gating on lymphocytes
for CD4+ T-cells and then gating on CD4 T-cells for annexin
V versus 7-AAD,was performed. This was in order to detect
Annexin V + 7-AAD negative cells (apoptotic cells), Annexin
V negative 7-AAD positive cells (dead cells), and Annexin
V positive 7-AAD positive (secondary apoptotic or necrotic)
CD4 T-cells as shown in Figure 1. A total of 300,000 events
were acquired in order to analyse a minimum of 2000 CD4+
T-cells. CXP and FCS express V3 software programmes were
used to analyse flow cytometry data.
2.6. Markers of Disease and Immune Activation. CD4 T-cell
counts were determined by staining whole blood with Bec-
ton Dickinson (BD) MultiTest CD3-FITC/CD8-PE/CD45-
PerCP/CD4-APC reagent in BD TruCount tubes according
to the manufacturer’s instructions and analysed on a BD
FACSCalibur flow cytometer (BD Biosciences, San Jose, CA,
USA). HIV-1 RNA quantifications were performed using
1.0mL of plasma with the use of the Nuclisens Easy Q
HIV-1 v.1.2 kit (BioMerieux Inc., Boxtel, the Netherlands).
CD38 expression on CD8+ T-cells (CD38/8) was determined
by flow cytometry. Whole blood samples were incubated
with the monoclonal antibodies: CD8-Per-CP; and CD38-
APC; CD3-FITC (BD Biosciences, San Jose, CA, USA) and
analysed on a BD FACSCalibur instrument using BD Cell
Quest Pro (Version 2) software. Lymphocytes were gated on
forward versus side scatter, CD3, and CD8 expression.
2.7. D-Dimers. D-dimer, a marker of fibrinogen breakdown
and clot formation, thus an indirect marker of inflammation,
was determined by spectrophotometry using the IL-D-dimer
method. This is an automated immunoassay for quantitative
determination of D-dimers in plasma. Plasma from sodium
citrate blood samples wasmixed with latex reagent and buffer
all supplied by Beckman Coulter (Miami, FL, USA) and
agglutination, measured as decrease in absorbance, was read
at 405 nm using ACL TOP from Beckman Coulter (Miami,
FL, USA).
2.8. Statistical Analysis. The data was analysed using the
Graphpad Prism version 5 statistical analysis software. Com-
parisons between the groups (HIV+ and HIV−) were done.
Analysis of variance (ANOVA) was used to determine
whether the means of the two groups (HIV+ and HIV−)
differed significantly. Mann-Whitney nonparametric test and
spearman’s correlation were applied. Results were reported as
medians with interquartile ranges. A 5% or lower significance
level was used to determine significant findings (𝑃 ≤ 0.05).
3. Results
3.1. Demographics of Study Population. The participants’
demographics are summarized in Table 1.The group included
20 HIV positive and 20 controls most of whom were females
(Fisher’s test 𝑃 = 0.36). There was no significant (𝑃 > 0.05)
difference between the two groups in terms of age. Both
groups had similarmean ages: 31 years forHIV positive group
and 30 years for the control group. The HIV positive group
had a significantly (𝑃 = 0.0012) lower CD4 count compared
to the control group. The HIV positive group had a well-
maintained CD4 count averaging 464 cells/mm3 (median-
411 cell/mm3) and was clinically well. Median viral load was
45705 copies/mL. The control group had a high CD4 count
with an average of 746 cells/mm3 and was also clinically well.
3.2. %CD25 Expression in the HIV Positive and Control
Groups. The%CD25 expression before and after stimulation
with LPS and incubation with vitamin C and NAC of the
forty study participants is shown in Table 2 and illustrated
in Figure 2. Baseline (unstimulated) levels of activation were
not significantly different between the two groups (𝑃 = 0.40),
however, after stimulation, the HIV positive group showed
statistically significant increase in activation (𝑃 = 0.03) when
compared to the controls, which was not significant (𝑃 =
0.16). A significant difference was noted with the incubation
of LPS and vitamin C alone and NAC alone: in the control
group. Optimal levels of inhibition of activation in the HIV
group were achieved with the combination of NAC + vitamin
C (𝑃 = 0.0018).
3.3. The % Annexin V/7-AAD Staining for Early and Late
Apoptosis between the HIV Positive and Control Groups. The
% Annexin V/7-AAD staining before and after stimulation
with LPS and overnight incubation with vitamin C and NAC
is summarised in Tables 3 and 4, and Figures 3 and 4. For
early apoptosis, at baseline, the levels of annexin V+/7AAD-
staining were not significantly (𝑃 > 0.05) different between
the two groups; however, a significant difference was noted
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Figure 1: Gating strategy for activation (CD25) and apoptosis (annexin V/7-AAD). Plots (a) (side scatter versus forward scatter), (b) (bright
CD4+ cells gated from the CD45+ leukocytes), (c) (CD25+ cells gated from the CD4 gate) and (d) (early, late apoptosis, and dead cells gated
from CD4+ cells gate) show dot plots of whole blood used to set the quadrants.
Table 2: The %CD25 expression before and after overnight stimulation with LPS and incubation with vitamin C and/or NAC.
%CD25 HIV+ group Controls 𝑃 value between HIVand control
𝑃 value for LPS activation and
inhibition by antioxidants in
HIV group
𝑃 value for
control
Unstimulated 7.9 (7.1–14.4) 10.2 (7.8–14.4) 0.4047
LPS stimulated 12.5 (10.3–17.6) 11.6 (9.6–15.2) 0.6823 0.0337∗∗ 0.16
LPS + Vit C 15.2 (11.7–17.6) 8.6 (7.2–11.9) 0.0003∗∗ 0.4 0.01∗∗
LPS + NAC 9.0 (7.1–14.2) 9.9 (6.9–13.1) 0.9033 0.0416∗∗ 0.07
LPS + cocktail 6.0 (4.2–13.1) 9.1 (7.8–14.6) 0.0501 0.0018∗∗ 0.22
All the values are median (interquartile range) percentages of cells expressing CD25 of the HIV positive and control groups, unstimulated and stimulated with
LPS and incubated overnight. ∗∗Medians significant at 𝑃 < 0.05.
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Table 3: The % annexin V+/7-AAD− staining of the HIV positive and the control groups.
% Annexin V HIV positive group Control 𝑃 value (HIV and controls)
𝑃 value for LPS activation
and inhibition by
antioxidants in HIV+ group
𝑃-value for controls
Unstimulated 1.6 (0.9–4) 1.9 (1.2–2.3) 0.49
LPS-activated cells 3.3 (1.6–5.6) 2.5 (2.0–3.2) 0.17 0.11 0.007∗∗
LPS + VIT C 3.6 (1.9–4.2) 2.6 (2.1–3.4) 0.26 0.84 0.44
LPS + NAC 3.4 (1.2–4.3) 2.6 (2.2–3.4) 0.55 0.54 0.66
LPS + CKTL 1.8 (1.0–3.7) 1.9 (1.5–2.4) 0.96 0.02∗∗ 0.008∗∗
All the values are median (interquartile range) percentages of cells staining with annexin V/7-AAD− of the HIV positive and control groups, unstimulated and
stimulated with LPS and incubated overnight. ∗Medians are marginally significant at 𝑃 = 0.05. ∗∗Medians significant at 𝑃 < 0.05.
Table 4: The % annexin V+/7-AAD+ staining of the HIV positive and HIV negative groups.
%7-AAD HIV positive group Control 𝑃 value between HIVand control
𝑃 value for LPS activation
and inhibition by
antioxidants in HIV group
𝑃 values for the controls
Baseline 0.7 (0.4–2.2) 0.4 (0.3–0.5) 0.02∗∗
LPS-activated cells 1.9 (0.7–3.2) 0.6 (0.4–0.7) 0.0029∗∗ 0.10 0.14
LPS + VIT C 1.2 (0.7–2.7) 0.7 (0.4–1.0) 0.0048∗∗ 0.89 0.27
LPS + NAC 2.4 (1.0–3.4) 0.6 (0.4–0.8) 0.0003∗∗ 0.64 0.79
LPS + CKTL 1.8 (1.3–2.1) 0.7 (0.6–1.2) 0.0001∗∗∗ 0.76 0.56
The values are median (interquartile range) percentages of cells staining for both annexin V and 7-AAD of the HIV positive and control groups, unstimulated
and stimulated with LPS and incubated overnight. ∗∗Medians significant at 𝑃 < 0.05. ∗∗∗Medians significant at 𝑃 ≤ 0.0001.
after stimulation with LPS (𝑃 = 0.007) in the control
group. There was a significant difference after incubation
with LPS and a combination of NAC and vitamin C in
both groups. Importantly, the combination of vitamin C and
NAC significantly (𝑃 < 0.0001) reduced the annexin V+/7-
AAD- staining cells back to its unstimulated levels. NAC
and vitamin C in combination significantly (𝑃 = 0.007,
𝑃 = 0.002) decreased the staining of annexin V+/7-AAD-
cells. For late apoptosis, there was no significant difference
(𝑃 > 0.05) before stimulation with LPS and after stimulation
with LPS and incubationwith the antioxidants individually or
in combination, meaning that these antioxidants are effective
in limiting early apoptosis. This could help in retaining their
functionality and protecting them from early death.
3.4. OtherMarkers of Disease in HIV Infection. Table 5 shows
the values of other markers of disease and immune activation
in the cohort. When compared with the controls as expected,
the HIV positive individuals had significantly (𝑃 < 0.05)
lower CD4 counts. D-dimers, an indirect (marker of fibrino-
gen breakdown and clot formation) marker of inflammation,
was significantly (𝑃 < 0.05) higher in HIV positive patients
than in controls.
There was a strong inverse correlation between CD4
count and viral load (𝑟 = −0.62; 𝑃 = 0.03) and negative
correlation between CD4 count and %CD38/CD8+ (𝑟 =
−0.48; 𝑃 = 0.05). However, there was no correlation between
CD4 counts and D-dimers.
4. Discussion
Persistent immune activation characterises HIV infection
and is associated with the depletion of CD4+ T-cells,
increased risk of disease progression, and higher mortality.
The breakdown of gut mucosal integrity in early HIV infec-
tion results in translocation of microbial products such as
lipopolysaccharide (LPS) into the systemic circulation. This
is an important source of on-going immune stimulation. In
this study, therefore, we developed an assay to determine the
ability of CD4+ T-cells in HIV to be activated by LPS in vitro
and further to be inhibited by selected antioxidants.
LPS induced a significant increase in CD25 (activation
marker) expression in HIV infection when compared to that
of the controls (𝑃 = 0.68). Thus, at this stage of the infection,
with relatively well-maintained CD4 counts and no clinical
symptoms, CD4 T-cells in HIV infection retain the ability to
be activated, which was significantly reduced by NAC and a
combination of NAC and vitamin C. After incubation with
antioxidants and stimulation with LPS, interestingly, the HIV
positive group showed good responses to NAC alone and a
“cocktail” of NAC and vitamin C, with CD25 levels returning
to below baseline values, however, a similar effect could only
be demonstrated in the control group with vitamin C alone.
The combination of vitamin C and NAC was required to
achieve optimal inhibition of the LPS-induced-activation.
LPS induces activation of innate immune cells such as
monocytes and dendritic cells resulting in increased produc-
tion of proinflammatory cytokines consequently inducing
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Figure 2: The figure shows the median %CD25 expression on
CD4+ T cells under different experimental conditions for both HIV
positive and control groups. LPS induced a significant increase in
CD25 expression in HIV infection (𝑃 = 0.03) and this increase was
similar to that of the controls (𝑃 = 0.68). Red and black lines at the
top of the bars indicate significance.
oxidative stress.This leads to depletion of antioxidant defence
mechanisms and an increased susceptibility to apoptosis.
CD25 is a relatively late marker of activation [16]. In the study
by Tincati et al. on the effects of in vitro LPS stimulation on
T-cells in patients on HAART, significantly higher CD4+ and
CD8+ expressing HLA-DR and CD38+ expressing cells were
detected in low and intermediate responders compared to the
HIV negative group confirming a sustained immune activa-
tion inHIV infection [15].The current study confirms Tincati
et al. findings of increased LPS-induced immune activation
as measured by CD25 expression in HIV infection when
compared to controls. Furthermore, there was a significantly
(𝑃 < 0.05) increased immune activation expressed as CD38
in the HIV positive group when compared to the controls.
Annexin V staining was also significantly increased after
stimulation with LPS in HIV positive and control groups but
was more pronounced in the HIV positive group. NAC alone
and in combination with vitamin C significantly reduced
early apoptosis of CD4+ T-cells to a greater degree than
vitaminC alone.Moreover, LPS induced a significant increase
in 7-AAD staining in HIV infection, which was significantly
reduced by the antioxidants either alone or in combination.
This study demonstrates that LPSwas capable of inducing
CD4 T-cell activation and apoptosis in vitro as indicated
by increased CD25, annexin V, and 7-AAD, which was
ameliorated by the combination of antioxidants. In addition,
NAC alone significantly reduced LPS-induced activation and
apoptosis of CD4+ T-cells in HIV infection. Early work
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Figure 3: The figure shows the median % annexin V staining on
CD4+ T-cells under different experimental conditions for both HIV
positive and control groups. LPS induced a significant increase in
annexin V staining in the controls (𝑃 = 0.007) and this increase was
significantly reduced in both HIV positive and controls (𝑃 = 0.02;
𝑃 = 0.008, resp.) by a combination of vitamin C and NAC. Red and
blue lines at the top of the bars indicate significance.
Table 5: Other markers of disease in HIV infection in both the HIV
positive and control groups.
HIV positive group Control group 𝑃 value
D-dimers (mg/L) 0.23 (0.2-0.3) 0.21 (0.20–0.26) <0.0001∗∗
CD38/8 (%) 27.6 (17.5–44.0) 11.6 (7.3–15.8) <0.0001∗∗
The table shows the D-dimers and %CD38/8 in these groups expressed as
median (interquartile range). ∗∗indicates that the medians were significantly
different at 𝑃 = 0.05. CD38/8 was significantly different (𝑃 < 0.0001).
demonstrated that NAC administration to HIV positive
individuals was able to slow down CD4 decline in HIV
infection [17]. NACand glutathione have been shown to com-
pletely block activation-induced death and associated DNA
fragmentation in T-cell hybridomas, therefore implicating
redox regulation in the processes [18]. In addition, NAC has
been shown to directly scavenge free radicals by decreasing
hypochlorous acid produced by neutrophils [19, 20]. Cell
studies have indicated thatNACenhances intracellular killing
of bacteria by protecting the neutrophils and macrophages
from free radicals generated during phagocytosis [21]. In
support of the current study findings, NAC has been shown
previously to inhibit LPS-mediated activation; however, this
work was performed in rats kupffer cells [14]. The effect
of NAC on T-cell activation and apoptosis particularly in
the context of HIV infection is not well documented and
therefore the findings of this study may be of value in the
future management of persons living with HIV.
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Figure 4: The figure shows the median % annexin V+/7-AAD+
staining on CD4+ T-cells under different experimental conditions
for both HIV positive and control groups. LPS did not induce a
significant increase in annexin V+/7-AAD+ staining in both groups
(𝑃 > 0.05).
An important finding of this studywas that vitaminC had
no effect on LPS-induced activation when used alone in HIV,
butwhenused in combinationwithNAC (cocktail), it showed
a significant reduction in CD4+ T-cell activation levels.
Previous studies have reported clinical improvement in AIDS
patients whowillingly consumed high doses (500mg, 800mg
and 1 800mg) of ascorbic acid [22–25]. In addition vitamin
C has been shown to inhibit NF-𝜅B activation via multiple
stimuli including IL-1 and TNF in endothelial cell lines
ECV30VS and in primaryHUVECS [26]. Several studies have
shown that vitamin C inhibited T-cell pathways of apoptosis
which includes the upregulation of the antiapoptotic B-
cell lymphoma-2 (Bcl-2) protein expression levels [27–29].
Although vitamin C exhibits strong antioxidant properties,
it has been demonstrated in vitro that it can also act as a
prooxidant in the presence of free transition metals [30, 31].
In this setting, it generates hydroxyl radicals in a fenton-
like reaction. This could explain the cause of activation of
CD4+ T-cells when vitamin C was used alone in the current
study. In support of this, Bergman et al. demonstrated a
39% increase in apoptotic cells when cells were incubated
with 0.2mg/mL vitamin C for 24 hrs [32]. Previous data on
clinical trials using vitamin C have been conflicting. Some
authors have suggested that supplementation with vitamin
C is toxic [33, 34]. In this study, only low concentrations
(10mM) of vitamin C were utilized. Previous work in our
laboratory (results not shown) had demonstrated that higher
concentrations were toxic and able to cause activation and
even death of the cells. Thus, at higher doses, vitamin C is
likely to have a prooxidant effect which causes activation and
even death of cells.
Therefore, the current study has developed an important
assay that demonstrates the response of CD4+ T-cells to
LPS-induced stimulation and further showed the effects of
antioxidants in this process. The study was able to demon-
strate that at this stage of HIV infection, CD4+ T-cells were
able to respond to LPS-induced stimulation and antioxidants;
therefore, they do not appear “exhausted” at this stage of the
disease. However, it should be noted that LPS induced more
death in the form of annexin V+/7-AAD+ staining in the
HIV group than the control, suggesting that the cells may
have been “primed” for death previously in vivo. Vitamin
C alone did not inhibit LPS-induced activation in the HIV
group as it did in the controls; suggesting that the use of
vitamin C alone in HIV infection would not be of value. The
combination of NAC with vitamin C produced the greatest
level of inhibition of early apoptosis, suggesting a potential
beneficial effect of this cocktail in the management of this
stage of the infection. It is at this early stage of HIV infection
that the “cocktail” is being most effective and this study has
demonstrated beneficial effects of the cocktail in limiting
immune activation and early apoptosis. This way immune
cells can be rescued before irreversible damage to the cells
occurs.
Limitations of the study were that specific tests for diag-
nosing underlying subclinical infections could not be per-
formed and smoking and alcohol habits were not docu-
mented. Longitudinal cohort studies will be important to
determine the value of intervention with the combination
of anti-oxidants as described in this study, in HIV positive
persons with CD4 counts >350 cells/mm3.
5. Conclusion
This is an important assay that demonstrated the response
of CD4+ T-cells to LPS-induced stimulation and showed
the inhibitory effects of antioxidants. Certain combinations
of antioxidants could be important in reducing the harmful
effects of chronic immune activation and thereby limit CD4+
T-cell depletion. Importantly, the study showed that CD4+
T-cells of the HIV positive group responded better to a
combination of vitamin C and NAC. Therefore, appropriate
intervention at this asymptomatic stage could rescue the cells
before exhaustion and senescence set in.
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